 |
|
|
 |
.NEWS FROM SIO
SIO2022 Health and Safety Update  To the SIO Community,
As we enter the busy holiday season, public health and safety is top of mind for all of us. The recent news surrounding COVID-19 is a reminder that while we continue to navigate new challenges, the medical advances we have seen in the last year are making it possible for us to move forward as an IO community.
On behalf of the SIO Board of Directors and SIO2022 Program Committee, we want to reassure you that SIO is committed to holding a safe, enjoyable Annual Scientific Meeting in San Francisco, 3-7 February 2022.
As we make our final preparations for SIO2022, please know that the health of our attendees is our first priority. SIO continues to pay close attention to CDC guidance, as well as relevant guidelines in the locale of the meeting. To date, the California Public Health Department is recording 77% of the state's population to be vaccinated and is not recommending a change in plans for public events, including conferences.
As part of our commitment to your safety, all attendees joining us in San Francisco will be required to provide proof of vaccination against COVID-19 or provide a negative PCR COVID-19 test within 24 hours of the start of the meeting.
|
|
.INDUSTRY NEWS
|
|
 |
|
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases.
|
|
|
|
|
Prediction of Post Transarterial Chemoembolization MR Images of Hepatocellular Carcinoma Using Spatio-Temporal Graph Convolutional Networks
PLoS One via PubMed
Magnetic resonance imaging (MRI) plays a critical role in the planning and monitoring of hepatocellular carcinomas (HCC) treated with locoregional therapies, in order to assess disease progression or recurrence. Dynamic contrast-enhanced (DCE)-MRI sequences offer temporal data on tumor enhancement characteristics which has strong prognostic value. Yet, predicting follow-up DCE-MR images from which tumor enhancement and viability can be measured, before treatment of HCC actually begins, remains an unsolved problem given the complexity of spatial and temporal information.
|
|
Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma
International Journal of Molecular Sciences via PubMed
Because diagnostic tools for discriminating between hepatocellular carcinoma (HCC) and advanced cirrhosis are poor, HCC is often detected in a stage where transarterial chemoembolization (TACE) is the best treatment option, even though it provides a poor survival gain. Despite having been used worldwide for several decades, TACE still has many limitations.
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063 |
